Tar­get­ing CD47? UCLA joins band­wag­on, with gel to stem tu­mors from resur­fac­ing

Hit­ting the “don’t eat me” CD47 re­cep­tor tar­get has gal­va­nized an army of drug de­vel­op­ers who want to make in­roads in the bur­geon­ing field of can­cer im­munother­a­py by off­set­ting im­muno­sup­pres­sion. But in an ef­fort to sub­vert side ef­fects that can be caused by the sys­temic ab­sorp­tion of such an­tag­o­nists, re­searchers are test­ing a gel that could be sprayed on pa­tients who have un­der­gone surgery to in­hib­it tu­mor re­cur­rence and metas­ta­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER